A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer

A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer

Abstract Triple‐positive breast cancer (TPBC) poorly responds to current standard neoadjuvant therapy (trastuzumab plus pertuzumab and chemotherapy). Our previous MUKDEN 01 study showed a promising total pathological complete response (tpCR) rate of 30.4% with neoadjuvant pyrotinib (pan‐human epider...

Full description

Bibliographic Details
Main Authors: Shiwen Huo, Jinqi Xue, Shuo Wang, Huilian Shan, Guanglei Chen, Nan Niu, Yimin Wang, Fang Qiu, Yi Zhao, Fei Xing, Xinyu Zheng, Wei Tu, Ke Li, Hai Zhao, Meiyue Tang, Qianshi Xu, Chao Liu, Yafei Zhao, Xiaofan Jiang, Zheng Pang, Keliang Zhang, Dianlong Zhang, Zhe‐Sheng Chen, Caigang Liu
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:MedComm
Subjects:
dalpiciclib
letrozole
neoadjuvant therapy
pyrotinib
trastuzumab
triple‐positive breast cancer
Online Access:https://doi.org/10.1002/mco2.505

Internet

https://doi.org/10.1002/mco2.505

Similar Items